Study to Evaluate Daptomycin Given During Dialysis and After Dialysis

Inclusion Criteria:

- Written informed consent prior to any study-related procedure not part of normal
medical care;

- Male or female ≥ 18 years of age;

- If female of childbearing potential; willing to practice reliable birth control
measures during study treatment and for at least 28 days after study completion, not
lactating or pregnant, and has a documented negative pregnancy test result within 24
hours prior to study medication administration;

- End-stage renal disease on stable (for at least 2 weeks) hemodialysis regimen, three
times weekly using high-flux membranes;

- Functioning hemodialysis access (for example, graft or fistula);

- Considered to be in appropriate health for study entry by the Investigator (for
example, no acute, debilitating medical problems) and appropriate candidate for
completing study treatment;

- If taking concomitant medications, subject must be on a relatively stable dose for at
least two weeks prior to study drug administration.

Exclusion Criteria:

- Received an investigational drug (including experimental biologic agents) within 30
days of study drug administration;

- Has received any dose of daptomycin within 7 days prior to study drug administration;

- Known to be allergic or intolerant to daptomycin;

- Evidence of active ongoing infection;

- Known human immunodeficiency virus (HIV) infection with CD4 count ≤ 200 cells/mm3;

- Active illicit drug use or alcohol abuse;

- Myocardial infarction within last 6 months;

- Subject with a history of muscular disease (for example, polymyositis, muscular
dystrophy);

- Subject with a history of neurological disease (for example, Guillain Barré, multiple
sclerosis), except stroke > 6 months prior to study entry;

- Intramuscular injection within 7 days of study drug administration;

- Body mass index (BMI) ≤ 18.5 or ≥ 40 kg/m2 (BMI = weight [kg]/height [m2]);

- WBC ≥ 12, 000 cells/mm3 or ≤ 2500 cells/ mm3;

- Neutropenic subject with absolute neutrophil count ≤ 500 cells/mm3;

- Baseline CPK values ≥ 3X ULN (upper limit of normal);

- Alanine aminotransferase (ALT) > 5XULN;

- Aspartate aminotransferase (AST) > 5XULN;

- Hemoglobin ≤ 9 gm/dL;

- Is considered unlikely to comply with study procedures or to return for scheduled
post-treatment evaluations;

- History of rhabdomyolysis.